Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Dementia

Does depression predict donepezil response in MCI?

Nature Reviews Neurology volume 5, pages 585–586 (2009)Cite this article

Data from a large multicenter study demonstrate that donepezil can delay the rate of progression from mild cognitive impairment to Alzheimer disease in patients with depressive symptoms, but not in individuals without notable depression. How important are these findings for clinical practice in neurology and psychiatry?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Petersen, R. C. et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352, 2379–2388 (2005).

    Article  CAS  Google Scholar 

  2. Lu, P. H. et al. Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology 72, 2115–2121 (2009).

    Article  CAS  Google Scholar 

  3. Birks, J. & Flicker, L. Donepezil for mild cognitive impairment. Cochrane Database of Systematic Reviews, Issue 3. Art No.: CD006104. doi:10.1002/14651858.CD006104 (2006).

    Google Scholar 

  4. Raschetti, R., Albanese, E., Vanacore, N. & Maggini, M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med. 4, e338 (2007).

    Article  Google Scholar 

  5. Barnes, D. E., Alexopoulos, G. S., Lopez, O. L., Williamson, J. D. & Yaffe, K. Depressive symptoms, vascular disease and mild cognitive impairment. Arch. Gen. Psychiatry 63, 273–279 (2006).

    Article  Google Scholar 

  6. Panza, F. et al. Depressive symptoms, vascular risk factors and mild cognitive impairment. The Italian longitudinal study on aging. Dement. Geriatr. Cogn. Disord. 25, 336–346 (2008).

    Article  Google Scholar 

  7. Ravaglia, G. et al. Prevalent depressive symptoms as a risk factor for conversion to mild cognitive impairment in an elderly Italian cohort. Am. J. Geriatr. Psychiatry 16, 834–843 (2008).

    Article  Google Scholar 

  8. Feldman, H. H. et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 6, 501–512 (2007).

    Article  CAS  Google Scholar 

  9. Holmes, C. et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 63, 214–219 (2004).

    Article  CAS  Google Scholar 

  10. Katona, C. et al. International Psychogeriatric Association consensus statement on defining and measuring treatment benefits in dementia. Int. Psychogeriatr. 19, 345–354 (2007).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Mental Health Sciences, University College London, London, UK

    Cornelius Katona

Authors
  1. Cornelius Katona
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cornelius Katona.

Ethics declarations

Competing interests

C. Katona has acted on the speaker's bureau for Boehringer Ingelheim, Eisai, Eli Lilly, Lundbeck and Novartis. He has also acted as a consultant for Boehringer Ingelheim, Eli Lilly and Lundbeck, and received research support from the latter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Katona, C. Does depression predict donepezil response in MCI?. Nat Rev Neurol 5, 585–586 (2009). https://doi.org/10.1038/nrneurol.2009.164

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2009.164

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing